Carcinoid Tumor  >>  Torisel (temsirolimus)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00112476: Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Checkmark In pts with mRCC & soft tissue sarcoma
Mar 2014 - Mar 2014: In pts with mRCC & soft tissue sarcoma
Completed
1
24
US
bryostatin 1, B705008K112, BRYO, Bryostatin, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Melanoma, Recurrent Renal Cell Cancer, Stage IV Melanoma, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
07/10
 
NCT00349206: Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Completed
1
69
US
sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
02/12
02/12
NCT01155258: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed
1
19
US
temsirolimus, CCI-779, cell cycle inhibitor 779, rapamycin analog CCI-779, Torisel, vinorelbine ditartrate, Biovelbin, Eunades, navelbine ditartrate, NVB, vinorelbine tartrate, VNB
University of Southern California, Wyeth is now a wholly owned subsidiary of Pfizer
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pheochromocytoma, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Small Cell Lung Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Regional Pheochromocytoma, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage III Uterine Sarcoma, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Endometrial Carcinoma, Stage IV Neuroendocrine Carcinoma of the Skin, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Thyroid Gland Medullary Carcinoma
01/13
05/14
NCT01548482: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
21
Canada
Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Trebananib, AMG 386, Angiopoietin 1/2-Neutralizing Peptibody AMG 386
National Cancer Institute (NCI)
Adult Solid Neoplasm, Lung Carcinoid Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Sarcoma, Stage III Renal Cell Cancer, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IV Renal Cell Cancer, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma
01/14
01/14

Download Options